Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2018 - 04 - 11
点击次数: 0
Positions: Managing Director
Company: Morningside
个人简介:
Lily joined Morningside in 2010 and serves as board directors in ten Morningside portfolio companies. She has worked in life science industry for more than 13 years with rich experience in new drug R&D management and regulatory affairs in China. Lily received her master degree in Biochemistry and Molecular Biology from Xi’an Jiaotong University in 2004, and M.B.A from Fudan University in 2011.
发布时间: 2018 - 04 - 11
点击次数: 0
Positions: Partner
Company: Eight Roads Ventures
个人简介:
Dr. Will Liu is a Partner of Eight Roads Ventures China, specializing in healthcare investment with twenty years of experience in the pharmaceutical and biotech industries.Prior to joining Eight Roads, Will held several positions of business development in multinational pharmaceutical companies, including Head of Worldwide Business Development for Neurosciences at GSK and Head of External Innovation China at Merck KGaA. Will was trained as a scientist and worked in drug discovery for over ten years.Will graduated from Nankai University in China and received his Ph.D. degree from the University of Michigan.
发布时间: 2018 - 04 - 11
点击次数: 0
Positions: Head of R&D, Vice President
Company: I-Mab Biopharma Co., Ltd
个人简介:
Joan obtained PhD in life science and license as a physician with board certification in US. She also had 3 postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. She practiced as a psychiatrist and worked in Eli Lilly & Co, Wyeth and Pfizer, where she was responsible for global clinical development programs cross phase 1-4. She has extensive experiences working with FDA, EMEA, CFDA, PMDA, KFDA and etc. She holds an academic position as the adjunctive professor in Indiana University School of Medicine.Joan was sent to China by Pfizer in 2011 as the China clinical head and joined Hengrui as the CMO in May 2013. She was granted the honor of “Talent of Innovation” by the “National Thousand Talent Program”. In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. She is also elected as the executive committee member of China New Drug Research Evaluation Committee. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China development head in 2015 and responsible for all the development programs, where she led multiple successful NDA approvals by CFDA. During this time, she is elected as the co-chair of RDPAC R&D core team. Most recently Joan I-Mab biopharma as the head of R&D and is leading the efforts of China to China and China to global.
发布时间: 2018 - 04 - 11
点击次数: 0
Positions: CEO/President
Company: McCull Pharmaceutical /  SUBIA-Sino-US Biomedical Investment Association
个人简介:
John Niu is a co-founder of BlueRock Venture Partners and focuses on advances in biotech and drug innovation. He has been actively identifying and evaluating new investments and has played key roles in launching, building and developing strategy of new companies. John is also the president and chief executive officer of McCull Pharmaceuticals and founding director at a number of startup biotech companies. Prior to the founding of BlueRock Venture Partners, John served as a Managing Director of GM Capital and as director and interim CEO of Chinda Biological. Prior to the founding of McCull Pharmaceuticals, John worked with Sanofi-Aventis and Merck and held a variety of roles of increasing responsibility in pharmaceutical research and development. John also played a key role in leading SUBIA (Sino-US Biomedical Investment Association) for promoting innovation and capital investment cross the border of US and China. John received his Ph.D in Chemistry and Toxicology from Iowa State University in US and a B.S. in Organic Chemistry from Zhengzhou University in China.John has over 20 years of experience in the pharmaceutical-biotechnology industry and assumed various active leadership roles as research scientist, executive, entrepreneur, and venture capitalist. He concentrates primarily on venture-funded biotech asset and early discovery platform with investment approaches of “Asset-Centic” and “Build-to-Exit” philosophy.As a serial entrepreneur, John founded PharmaSolution LLC in New Jersey in 2005, a Delaware incorporation - McCullough Pharmaceuticals Inc in 2008, McCull Nantong in 2011, and Rudong KeBio in 2015. He served as founding Director and CEO and played key role in the early sourcing, financing, launching and development of the start-up companies. In these roles, he was instrumental in formulating the initial business plan and assembling the founding team, and directed drug innovation and product development of recombinant proteins and antibodies anticancer-drugs and new anti-coagulation biochemical drugs. Through these endeavors, John gained extensive strategic and operational experience in startup biotech companies.Prior to the founding of McCull Pharmaceuticals, John worked with Sanofi-Aventis and Merck and held a variety of roles of increasing responsibility in pharmaceutical research as a research chemist, senior scientist, study director, and the Chair of the global CMC team. Through his career, he participated in a large number of R & D projects from small molecule to biochemical drug development. He gained broad expertise across all phases of drug discovery, early development and process sciences, As chairman of the global CMC team, he was responsible for coordinating activities for global strategic planning, technical development, outsourcing and cooperation with cross-department members from Chemical Development, Pilot Plant production, Toxicology,DMPK, Drug formulation, Analytical Science, Clinical Supply Chain, Regulatory Affairs, and GMP Compliance. While working at Sanofi-Aventis, he pursued his QA/RA MS program studies from Temple University School of Pharmacy and obtained the RA/QA certificate in May 2007. John started his pharma career with Sanofi in 1995, joined Aventis in 2008, and then entered Sanofi-Aventis at Bridgewater NJ in 2001 due to company merge.John received his Ph.D in Chemistry and Toxicology from Iowa State University, and a B.S. in Chemistry from Zhengzhou University. He had been a research staff at Ames Laboratory US-DOE since 1989 and was formerly a lecturer in Organic Chemistry at Zhengzhou University. John is an adjunct professor of Nantong University.